The Nuances of Hematologic Oncology Clinical Trials
White Paper
Nov 21, 2019
Investigating Candidate Treatments for Blood Cancers

Conducting effective clinical trials in hematologic malignancies requires an understanding of a rapidly evolving treatment paradigm that is increasingly nuanced, complex, and patient-directed.

Just as the underlying differences in biology and prevalence between blood cancers and solid tumors necessitates differences in treating patients, they also require specialized clinical and operational expertise within the proper conduct of clinical trials.

Biotech companies developing potential hematologic oncology therapies must adapt endpoints, study designs, and data management, as well as consider patients' experiences to address the challenges related to exploring these investigational agents for blood-based cancers. This paper examines the requirements for effectively and successfully conducting hematologic oncology clinical trials.